Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

Original reporting
Published Oct 21, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra Life falls as tissue reconstruction woes add to flooding worries in Q3 — source image
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings miss and flood‑related cost introduce near‑term downside risk, but the adjusted EPS beat and growth in Specialty Surgery provide a partial cushion.

02

Market read

The earnings release is the primary catalyst for IART's price movement today, with potential spill‑over to the broader MedTech sector.

03

What to watch

The Specialty Surgery segment posted a 4% YoY revenue increase, which could offset concerns if the tissue‑reconstruction unit recovers.

Relevance 7/10Novelty 8/10Timing: after‑hours reaction

Background

Integra LifeSciences (IART) is a MedTech company focused on neurosurgery and tissue reconstruction. The Q3 release includes both financial results and an operational disruption note.

Company-level read

Ticker impact

$IARTBearishMedium confidence
Context

Integra LifeSciences reported Q3 2026 results that missed revenue estimates and highlighted a $7M flood‑related impact on its Cincinnati facility.

Expected impact

likely pressure as investors price in the revenue shortfall and operational setback

Evidence & confidence

Revenue fell short of consensus and guidance was lowered; the flood hit adds a tangible cost drag, prompting short‑term sell‑off.

Market effects

MedTech and tissue‑reconstruction segments may see heightened scrutiny on supply‑chain resilience.

Cincinnati‑area industrial activity could face short‑term concerns, but limited broader regional effect.

Limited to investors tracking US‑listed MedTech earnings; no global macro impact.

Counterpoint

If the flood impact is one‑off, the stock may be oversold and could rebound on the back of a solid adjusted EPS beat.

Key entities

  • Integra LifeSciences

    US‑listed MedTech firm (ticker IART) reporting Q3 2026 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.